Bones, heart and the new anabolic agent romosozumab

Postgrad Med J. 2019 Oct;95(1128):521-523. doi: 10.1136/postgradmedj-2019-136699. Epub 2019 Aug 17.

Author

Michael Pazianas¹

Affiliation

¹ Musculoskeletal Institute, University of Oxford, Oxford, UK Michael.Pazianas@ndorms.ox.ac.uk.

PMID: 31422376
DOI: 10.1136/postgradmedj-2019-136699

No abstract available

Keywords: abaloparatide; bone anabolics; osteoporosis; pth; romosozumab; severe adverse effects.

Publication types

Editorial

MeSH terms

Anabolic Agents / pharmacology
Anabolic Agents / therapeutic use
Antibodies, Monoclonal / pharmacology
Antibodies, Monoclonal / therapeutic use*
Bone Density
Bone Density Conservation Agents / pharmacology
Bone Density Conservation Agents / therapeutic use*
Cardiovascular Diseases / chemically induced
Female
Humans
Osteoporosis, Postmenopausal / drug therapy*
Osteoporotic Fractures / prevention & control*

Substances

Anabolic Agents
Antibodies, Monoclonal
Bone Density Conservation Agents
romosozumab